Compare SPCB & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | RNXT |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 36.4M |
| IPO Year | N/A | 2021 |
| Metric | SPCB | RNXT |
|---|---|---|
| Price | $8.90 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $7.75 |
| AVG Volume (30 Days) | 73.4K | ★ 214.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $26,739,000.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | $27.13 | $272.69 |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.14 | $0.70 |
| 52 Week High | $18.95 | $1.69 |
| Indicator | SPCB | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 40.98 |
| Support Level | $8.64 | $0.92 |
| Resistance Level | $9.92 | $1.00 |
| Average True Range (ATR) | 0.49 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 28.62 | 17.21 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.